{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:31:17Z","timestamp":1789504277543,"version":"build-2803163510"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007224","name":"National Foundation for Science and Technology Development","doi-asserted-by":"publisher","award":["IBPG-1553-4.03\/19"],"award-info":[{"award-number":["IBPG-1553-4.03\/19"]}],"id":[{"id":"10.13039\/100007224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88882.380408\/2019 -01"],"award-info":[{"award-number":["88882.380408\/2019 -01"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["IBPG-0322-4.03\/21"],"award-info":[{"award-number":["IBPG-0322-4.03\/21"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["141307\/2020-0"],"award-info":[{"award-number":["141307\/2020-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["426065\/2018-2"],"award-info":[{"award-number":["426065\/2018-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.tube.2022.102208","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T02:34:32Z","timestamp":1651890872000},"page":"102208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Nanotechnology and tuberculosis: An old disease with new treatment strategies"],"prefix":"10.1016","volume":"135","author":[{"given":"Daniel Charles dos Santos","family":"Mac\u00eado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago Dillion Lima","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrelli Meridiana de F\u00e1tima Ramos dos Santos","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline Barbosa de","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane Cajub\u00e1 de Britto","family":"Lira Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella Mac\u00e1rio Ferro","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tube.2022.102208_bib1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1186\/s13104-018-3846-z","article-title":"Incidence of tuberculosis in children on antiretroviral therapy: a retrospective cohort study","volume":"11","author":"Endalamaw","year":"2018","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.tube.2022.102208_bib2","series-title":"Global tuberculosis report","author":"WHO","year":"2020"},{"issue":"5","key":"10.1016\/j.tube.2022.102208_bib3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.tube.2022.102208_bib4","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.tube.2022.102208_bib5","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1021\/acs.bioconjchem.6b00430","article-title":"Gold nanorods as drug delivery vehicles for rifampicin greatly improve the efficacy of combating Mycobacterium tuberculosis with good biocompatibility with the host cells","volume":"27","author":"Ali","year":"2016","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.tube.2022.102208_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.carbpol.2019.04.056","article-title":"Dual delivery of tuberculosis drugs via cyclodextrin conjugated curdlan nanoparticles to infected macrophages","volume":"218","author":"Basha","year":"2019","journal-title":"Carbohydr Polym"},{"issue":"3","key":"10.1016\/j.tube.2022.102208_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0041-3879(90)90078-M","article-title":"Distribution of liposomes in tuberculous mice","volume":"71","author":"Orozco","year":"1990","journal-title":"Tubercle"},{"key":"10.1016\/j.tube.2022.102208_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/828939","article-title":"Risk factors for tuberculosis","volume":"2013","author":"Narasimhan","year":"2013","journal-title":"Pulm. Med"},{"issue":"1645","key":"10.1016\/j.tube.2022.102208_bib9","doi-asserted-by":"crossref","first-page":"20130437","DOI":"10.1098\/rstb.2013.0437","article-title":"The ongoing challenge of latent tuberculosis","volume":"369","author":"Esmail","year":"2014","journal-title":"Philos Trans R Soc B: Biol Sci"},{"key":"10.1016\/j.tube.2022.102208_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.tube.2019.05.005","article-title":"Modeling of Mycobacterium tuberculosis dormancy in bacterial cultures","volume":"117","author":"Batyrshina","year":"2019","journal-title":"Tuberculosis"},{"issue":"7","key":"10.1016\/j.tube.2022.102208_bib11","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.tube.2022.102208_bib12","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ajem.2019.12.040","article-title":"Tuberculosis: a focused review for the emergency medicine clinician","volume":"38","author":"Long","year":"2020","journal-title":"Am J Emerg Med"},{"issue":"6","key":"10.1016\/j.tube.2022.102208_bib13","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.4049\/jimmunol.1501612","article-title":"Cutting edge: Mycobacterium tuberculosis induces aerobic glycolysis in human alveolar macrophages that is required for control of intracellular bacillary replication","volume":"196","author":"Gleeson","year":"2016","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.tube.2022.102208_bib14","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.celrep.2019.01.021","article-title":"HIV-1 and SIV infection are associated with early loss of lung interstitial CD4+ T cells and dissemination of pulmonary tuberculosis","volume":"26","author":"Corleis","year":"2019","journal-title":"Cell Rep"},{"issue":"37","key":"10.1016\/j.tube.2022.102208_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw6693","article-title":"Alveolar macrophages generate a noncanonical NRF2-driven transcriptional response to Mycobacterium tuberculosis in vivo","volume":"4","author":"Rothchild","year":"2019","journal-title":"Sci Immunol"},{"issue":"3","key":"10.1016\/j.tube.2022.102208_bib16","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.immuni.2021.01.003","article-title":"Early innate and adaptive immune perturbations determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection","volume":"54","author":"Xu","year":"2021","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.tube.2022.102208_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000407","article-title":"Human mucosal associated invariant T cells detect bacterially infected cells","volume":"8","author":"Gold","year":"2010","journal-title":"PLoS Biol"},{"issue":"9","key":"10.1016\/j.tube.2022.102208_bib18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/cmi.12480","article-title":"The innate immune response in human tuberculosis","volume":"17","author":"Lerner","year":"2015","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.tube.2022.102208_bib19","first-page":"185","article-title":"Innate immune recognition in tuberculosis infection","volume":"653","author":"Tsolaki","year":"2009","journal-title":"Target Pattern Recogn Innate Immun"},{"key":"10.1016\/j.tube.2022.102208_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/791392","article-title":"The role of airway epithelial cells in response to mycobacteria infection","author":"Li","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"4","key":"10.1016\/j.tube.2022.102208_bib21","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/imm.12223","article-title":"Early clearance of M ycobacterium tuberculosis: a new frontier in prevention","volume":"141","author":"Verrall","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.tube.2022.102208_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.micpath.2018.10.030","article-title":"PE17 protein from Mycobacterium tuberculosis enhances Mycobacterium smegmatis survival in macrophages and pathogenicity in mice","volume":"126","author":"Li","year":"2019","journal-title":"Microb Pathog"},{"key":"10.1016\/j.tube.2022.102208_bib23","doi-asserted-by":"crossref","first-page":"104412","DOI":"10.1016\/j.meegid.2020.104412","article-title":"Mycobacterium tuberculosis Rv3717 enhances the survival of Mycolicibacterium smegmatis by inhibiting host innate immune and caspase-dependent apoptosis","volume":"84","author":"Gong","year":"2020","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.tube.2022.102208_bib24","doi-asserted-by":"crossref","first-page":"126674","DOI":"10.1016\/j.micres.2020.126674","article-title":"Human tuberculosis and Mycobacterium tuberculosis complex: a review on genetic diversity, pathogenesis and omics approaches in host biomarkers discovery","volume":"246","author":"Kanabalan","year":"2021","journal-title":"Microbiol Res"},{"issue":"1\u20132","key":"10.1016\/j.tube.2022.102208_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tube.2003.08.003","article-title":"M. tuberculosis persistence, latency, and drug tolerance","volume":"84","author":"Gomez","year":"2004","journal-title":"Tuberculosis"},{"issue":"1","key":"10.1016\/j.tube.2022.102208_bib26","first-page":"1","article-title":"Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study. BMC Pharmacol","volume":"20","author":"Shibeshi","year":"2019","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.tube.2022.102208_bib27","first-page":"279","article-title":"Second-line injectable induced ototoxicity in drug resistant tuberculosis: a systematic review of Indian studies. Indian","volume":"66","author":"Sarin","year":"2019","journal-title":"J Tuberc"},{"issue":"4","key":"10.1016\/j.tube.2022.102208_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"28","key":"10.1016\/j.tube.2022.102208_bib29","doi-asserted-by":"crossref","first-page":"e7482","DOI":"10.1097\/MD.0000000000007482","article-title":"Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: a retrospective study","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.tube.2022.102208_bib30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/cid\/cir889","article-title":"Totally drug-resistant tuberculosis in India","volume":"54","author":"Udwadia","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2022.102208_bib31","doi-asserted-by":"crossref","first-page":"109777","DOI":"10.1016\/j.msec.2019.109777","article-title":"Mannosylated graphene oxide as macrophage-targeted delivery system for enhanced intracellular M. tuberculosis killing efficiency","volume":"103","author":"Pi","year":"2019","journal-title":"Mater Sci Eng C"},{"issue":"1","key":"10.1016\/j.tube.2022.102208_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.tube.2022.102208_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2016.09.017","article-title":"Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives","volume":"241","author":"Alexander","year":"2016","journal-title":"J Contr Release"},{"key":"10.1016\/j.tube.2022.102208_bib34","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jconrel.2020.09.020","article-title":"Zero-order drug delivery: state of the art and future prospects","volume":"327","author":"Laracuente","year":"2020","journal-title":"J Contr Release"},{"key":"10.1016\/j.tube.2022.102208_bib35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jconrel.2020.02.026","article-title":"Antitubercular nanocarrier monotherapy: study of in vivo efficacy and pharmacokinetics for rifampicin","volume":"321","author":"Trousil","year":"2020","journal-title":"J Contr Release"},{"issue":"1","key":"10.1016\/j.tube.2022.102208_bib36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejpb.2011.02.013","article-title":"Cytotoxicity and cellular uptake of newly synthesized fucoidan-coated nanoparticles","volume":"79","author":"Lira","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"10.1016\/j.tube.2022.102208_bib37","first-page":"239","article-title":"Formulation of dry powder inhaler of anti-tuberculous drugs using spray drying technique and optimization using 23 level factorial design approach. Curr","volume":"14","author":"Thakkar","year":"2019","journal-title":"Drug Ther"},{"issue":"7","key":"10.1016\/j.tube.2022.102208_bib38","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.xphs.2020.03.018","article-title":"Intramacrophage delivery of dual drug loaded nanoparticles for effective clearance of Mycobacterium tuberculosis","volume":"109","author":"Jahagirdar","year":"2020","journal-title":"J Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.tube.2022.102208_bib39","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00270-018-1899-y","article-title":"Pickering-emulsion for liver trans-arterial chemo-embolization with oxaliplatin","volume":"41","author":"Deschamps","year":"2018","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"10.1016\/j.tube.2022.102208_bib40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.drudis.2019.11.001","article-title":"Enhancing the potential preclinical and clinical benefits of quercetin through novel drug delivery systems","volume":"25","author":"Khursheed","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.tube.2022.102208_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jddst.2018.07.001","article-title":"In vivo drug delivery efficiency of albumin-encapsulated liposomes as hydrophobic drug carriers","volume":"47","author":"Okamoto","year":"2018","journal-title":"J Drug Deliv Sci Technol"},{"issue":"2","key":"10.1016\/j.tube.2022.102208_bib42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1574-695X.1994.tb00433.x","article-title":"Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A","volume":"8","author":"Singh","year":"1994","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"16","key":"10.1016\/j.tube.2022.102208_bib43","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/0264-410X(95)00084-E","article-title":"Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles","volume":"13","author":"Vordermeier","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2022.102208_bib44","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jddst.2019.05.025","article-title":"Alginate modified-PLGA nanoparticles entrapping amikacin and moxifloxacin as a novel host-directed therapy for multidrug-resistant tuberculosis","volume":"52","author":"Abdelghany","year":"2019","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.tube.2022.102208_bib45","doi-asserted-by":"crossref","first-page":"102698","DOI":"10.1016\/j.jddst.2021.102698","article-title":"Fucoidan-coated PIBCA nanoparticles containing oncocalyxone A: activity against metastatic breast cancer cells","volume":"65","author":"Cavalcanti","year":"2021","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"10.1016\/j.tube.2022.102208_bib46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jpha.2020.05.002","article-title":"Current status of in vivo bioanalysis of nano drug delivery systems","volume":"10","author":"Wang","year":"2020","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.tube.2022.102208_bib47","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ijbiomac.2020.05.192","article-title":"A systematic study on chitosan-liposome based systems for biomedical applications","volume":"160","author":"Kumar","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.tube.2022.102208_bib48","article-title":"Recent advances in inhalable liposomes for treatment of pulmonary diseases: concept to clinical stance","volume":"56","author":"Mehta","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.tube.2022.102208_bib49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jconrel.2014.04.009","article-title":"Nanostructured drug delivery for better management of tuberculosis","volume":"184","author":"Kaur","year":"2014","journal-title":"J Contr Release"},{"issue":"5","key":"10.1016\/j.tube.2022.102208_bib50","doi-asserted-by":"crossref","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013007419","article-title":"A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach","volume":"30","author":"Hamidi","year":"2013","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.tube.2022.102208_bib51","doi-asserted-by":"crossref","first-page":"109607","DOI":"10.1016\/j.eurpolymj.2020.109607","article-title":"Carbohydrate polymer-based nanoparticle application in drug delivery for CNS-related disorders","volume":"128","author":"Ansari","year":"2020","journal-title":"Eur Polym J"},{"issue":"8","key":"10.1016\/j.tube.2022.102208_bib52","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.eurpolymj.2013.04.033","article-title":"Designing polymeric microparticles for biomedical and industrial applications","volume":"49","author":"Campos","year":"2013","journal-title":"Eur Polym J"},{"key":"10.1016\/j.tube.2022.102208_bib53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.carbpol.2017.03.033","article-title":"Alginate microparticles as oral colon drug delivery device: a review","volume":"168","author":"Ag\u00fcero","year":"2017","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.tube.2022.102208_bib54","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/374252","article-title":"Stealth properties to improve therapeutic efficacy of drug nanocarriers","author":"Salmaso","year":"2013","journal-title":"J Drug Deliv"},{"issue":"5\u20136","key":"10.1016\/j.tube.2022.102208_bib55","article-title":"Stealth engineering for in vivo drug delivery systems","volume":"43","author":"Mohapatra","year":"2015","journal-title":"Crit Rev Biomed Eng"},{"issue":"1","key":"10.1016\/j.tube.2022.102208_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40824-019-0166-x","article-title":"Therapeutic efficacy of nanoparticles and routes of administration","volume":"23","author":"Chenthamara","year":"2019","journal-title":"Biomater Res"},{"key":"10.1016\/j.tube.2022.102208_bib57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cej.2017.12.110","article-title":"New active formulations against M. tuberculosis: bedaquiline encapsulation in lipid nanoparticles and chitosan nanocapsules","volume":"340","author":"De Matteis","year":"2018","journal-title":"Chem Eng J"},{"issue":"1","key":"10.1016\/j.tube.2022.102208_bib58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/03639045.2018.1513025","article-title":"Inhalable liposomes of Glycyrrhiza glabra extract for use in tuberculosis: formulation, in vitro characterization, in vivo lung deposition, and in vivo pharmacodynamic studies","volume":"45","author":"Viswanathan","year":"2019","journal-title":"Drug Dev Ind Pharm"},{"issue":"5","key":"10.1016\/j.tube.2022.102208_bib59","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1590\/0074-02760150454","article-title":"Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates","volume":"111","author":"Ferraz-Carvalho","year":"2016","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"1\u20132","key":"10.1016\/j.tube.2022.102208_bib60","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijpharm.2017.04.074","article-title":"Preparation and characterization of isoniazid-loaded crude soybean lecithin liposomes","volume":"526","author":"Nkanga","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.tube.2022.102208_bib61","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jddst.2018.03.016","article-title":"pH-Dependent release of isoniazid from isonicotinic acid (4-hydroxy-benzylidene) - hydrazide loaded liposomes","volume":"45","author":"Nkanga","year":"2018","journal-title":"J Drug Deliv Sci Technol"},{"issue":"10","key":"10.1016\/j.tube.2022.102208_bib62","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2017.01.079","article-title":"Protective efficacy of a lipid antigen vaccine in a Guinea pig model of tuberculosis","volume":"35","author":"Larrouy-Maumus","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2022.102208_bib63","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.2147\/IJN.S163925","article-title":"Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against Mycobacterium tuberculosis H37Rv strain","volume":"13","author":"Hakkimane","year":"2018","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.tube.2022.102208_bib64","doi-asserted-by":"crossref","first-page":"102013","DOI":"10.1016\/j.jddst.2020.102013","article-title":"Inhalable linezolid loaded PLGA nanoparticles for treatment of tuberculosis: design, development and in vitro evaluation","volume":"60","author":"Shah","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.tube.2022.102208_bib65","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jconrel.2020.08.022","article-title":"In vitro and in vivo antitubercular activity of benzothiazinone-loaded human serum albumin nanocarriers designed for inhalation","volume":"328","author":"Patel","year":"2020","journal-title":"J Contr Release"},{"issue":"1","key":"10.1016\/j.tube.2022.102208_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-31316-6","article-title":"Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1","volume":"8","author":"Richter","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.tube.2022.102208_bib67","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jddst.2019.05.052","article-title":"Streptomycin sulfate dry powder inhalers for the new tuberculosis treatment schedule","volume":"52","author":"Shiehzadeh","year":"2019","journal-title":"J Drug Deliv Sci Technol"},{"issue":"6","key":"10.1016\/j.tube.2022.102208_bib68","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1021\/acsnano.7b08264","article-title":"Multimetallic microparticles increase the potency of rifampicin against intracellular Mycobacterium tuberculosis","volume":"12","author":"Ellis","year":"2018","journal-title":"ACS Nano"},{"issue":"1\u20132","key":"10.1016\/j.tube.2022.102208_bib69","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijpharm.2017.06.088","article-title":"Dual antibiotherapy of tuberculosis mediated by inhalable locust bean gum microparticles","volume":"529","author":"Rodrigues","year":"2017","journal-title":"Int J Pharm."},{"issue":"8","key":"10.1016\/j.tube.2022.102208_bib70","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/03639045.2019.1608231","article-title":"Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment","volume":"45","author":"Cunha","year":"2019","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.tube.2022.102208_bib71","author":"Lawlor"},{"issue":"1","key":"10.1016\/j.tube.2022.102208_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-019-1552-3","article-title":"Potential active targeting of gatifloxacin to macrophages by means of surface-modified PLGA microparticles destined to treat tuberculosis","volume":"21","author":"Marcianes","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.tube.2022.102208_bib73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejpb.2018.10.020","article-title":"Inhalable poly (lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection","volume":"134","author":"O'Connor","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.tube.2022.102208_bib74","article-title":"Development and optimization of stealth liposomal system for enhanced in vitro cytotoxic effect of quercetin","volume":"55","author":"Saraswat","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"issue":"2","key":"10.1016\/j.tube.2022.102208_bib75","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jconrel.2011.10.037","article-title":"State of the art in PEGylation: the great versatility achieved after forty years of research","volume":"161","author":"Pasut","year":"2012","journal-title":"J Contr Release"},{"key":"10.1016\/j.tube.2022.102208_bib76","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.colsurfb.2017.07.014","article-title":"Contribution of Kupffer cells to liposome accumulation in the liver","volume":"158","author":"Samuelsson","year":"2017","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"3","key":"10.1016\/j.tube.2022.102208_bib77","first-page":"374","article-title":"Critical physicochemical attributes of chitosan nanoparticles admixed lactose-PEG 3000 microparticles in pulmonary inhalation","volume":"15","author":"Alhajj","year":"2020","journal-title":"Asian J Pharm Sci"},{"issue":"1\u20132","key":"10.1016\/j.tube.2022.102208_bib78","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijpharm.2013.01.038","article-title":"In vivo\/in vitro pharmacokinetic and pharmacodynamics study of spray-dried poly-(DL-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid","volume":"444","author":"Booysen","year":"2013","journal-title":"Int J Pharm."},{"key":"10.1016\/j.tube.2022.102208_bib79","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.colsurfb.2012.12.008","article-title":"Isoniazid loaded core shell nanoparticles derived from PLGA\u2013PEG\u2013PLGA tri-block copolymers: in vitro and in vivo drug release","volume":"104","author":"Gajendiran","year":"2013","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"20","key":"10.1016\/j.tube.2022.102208_bib80","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1016\/j.bmcl.2015.08.046","article-title":"Development of a three component complex to increase isoniazid efficacy against isoniazid resistant and nonresistant Mycobacterium tuberculosis","volume":"25","author":"Manning","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.tube.2022.102208_bib81","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2019.05.019","article-title":"Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR\/Cas9 system suppressed the metastasis of pancreatic cancer","volume":"304","author":"Li","year":"2019","journal-title":"J Contr Release"},{"issue":"4","key":"10.1016\/j.tube.2022.102208_bib82","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood\u2013brain barrier to blood\u2013brain interface: new opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.tube.2022.102208_bib83","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jconrel.2019.11.037","article-title":"Dual and multi-targeted nanoparticles for site-specific brain drug delivery","volume":"317","author":"Luo","year":"2020","journal-title":"J Contr Release"},{"key":"10.1016\/j.tube.2022.102208_bib84","article-title":"Progresses in targeted drug delivery systems using chitosan nanoparticles in cancer therapy: a mini-review","volume":"58","author":"Rostami","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"issue":"7607","key":"10.1016\/j.tube.2022.102208_bib85","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic Diken RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.tube.2022.102208_bib86","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.addr.2020.06.024","article-title":"Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications","volume":"156","author":"Chung","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"10.1016\/j.tube.2022.102208_bib87","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ijpharm.2016.09.080","article-title":"Targeted delivery of rifampicin to tuberculosis-infected macrophages: design, in-vitro, and in-vivo performance of rifampicin-loaded poly (ester amide) s nanocarriers","volume":"513","author":"Praphakar","year":"2016","journal-title":"Int J Pharm."},{"issue":"19","key":"10.1016\/j.tube.2022.102208_bib88","first-page":"11324","article-title":"Zn 2+ cross-linked sodium alginate-g-allylamine-mannose polymeric carrier of rifampicin for macrophage targeting tuberculosis nanotherapy. New J","volume":"41","author":"Praphakar","year":"2017","journal-title":"Inside Chem"},{"issue":"8","key":"10.1016\/j.tube.2022.102208_bib89","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1166\/jbn.2021.3139","article-title":"Fucoidan-coated liposomes: a target system to deliver the antimicrobial drug usnic acid to macrophages infected with Mycobacterium tuberculosis","volume":"17","author":"Salviano","year":"2021","journal-title":"J Biomed Nanotechnol"},{"issue":"1\u20132","key":"10.1016\/j.tube.2022.102208_bib90","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ijpharm.2017.06.045","article-title":"Surface engineering of Solid Lipid Nanoparticle assemblies by methyl \u03b1-d-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy","volume":"528","author":"Maretti","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.tube.2022.102208_bib91","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijbiomac.2018.10.167","article-title":"Sericin-chitosan doped maleate gellan gum nanocomposites for effective cell damage in Mycobacterium tuberculosis","volume":"122","author":"Mehnath","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.tube.2022.102208_bib92","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2019.11.009","article-title":"Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: therapeutic assessment in a murine model of tuberculosis infection","volume":"147","author":"Grenha","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20133","key":"10.1016\/j.tube.2022.102208_bib93","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0168-3659(01)00549-1","article-title":"Targeting to macrophages: role of physicochemical properties of particulate carriers\u2014liposomes and microspheres\u2014on the phagocytosis by macrophages","volume":"79","author":"Ahsan","year":"2002","journal-title":"J Contr Release"},{"issue":"2\u20133","key":"10.1016\/j.tube.2022.102208_bib94","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0304-4165(02)00319-7","article-title":"The mannose receptor family","volume":"1572","author":"East","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.tube.2022.102208_bib95","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2020.05.013","article-title":"Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defence peptide (HDP) in experimental tuberculosis","volume":"324","author":"Sharma","year":"2020","journal-title":"J Contr Release"},{"issue":"5","key":"10.1016\/j.tube.2022.102208_bib96","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/psc.2708","article-title":"Peptide IDR\u20101018: modulating the immune system and targeting bacterial biofilms to treat antibiotic\u2010resistant bacterial infections","volume":"21","author":"Mansour","year":"2015","journal-title":"J Pept Sci"},{"issue":"3","key":"10.1016\/j.tube.2022.102208_bib97","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11101-020-09717-1","article-title":"Usnic acid: from an ancient lichen derivative to promising biological and nanotechnology applications","volume":"20","author":"Macedo","year":"2021","journal-title":"Phytochemistry Rev"},{"key":"10.1016\/j.tube.2022.102208_bib98","series-title":"Methods of treatment using human anti-IL-23 antibodies. United States patent US 10954297B2","author":"Benson","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib99","series-title":"Compounds and therapeutic uses thereof. United States patent US 10953100B2","author":"Pickford","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib100","series-title":"Lipid compositions. United States patent US 10953095B2","author":"Manoharan","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib101","series-title":"Synthetic immunogens for prophylaxis or treatment of tuberculosis. United States patent US 10953079B2","author":"Weiner","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib102","series-title":"United States patent US 10952967B2","author":"Sirianni","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib103","series-title":"Compositions and methods for drug delivery. United States patent US 10952965B2","author":"Rabinow","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib104","series-title":"Interferon production using short RNA duplexes. United States patent US 10947543B2","author":"Pyle","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib105","series-title":"Platform for generating safe cell therapeutics. United States patent US 10947507B2","author":"Klemke","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib106","series-title":"Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components. United States patent US 10946108B2","author":"Zhang","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib107","series-title":"United States patent US 10946091B2","author":"Agrawal","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib108","series-title":"United States patent US 10946082B2","author":"Agrawal","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib109","series-title":"Production of stable non-polyadenylated RNAs. United States patent US 10946035B2","author":"Wilusz","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib110","series-title":"Controlled-release peptide compositions and uses thereof. United States patent US 10945962B2","author":"Vetro","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib111","series-title":"inventors; Caris Science Inc. Aptamers and uses thereof. United States patent US 10942184B2","author":"Halbert","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib112","series-title":"Treatment of angiopoietin like 7 (ANGPTL7) related diseases. United States patent US 10941404B2","author":"Gottesman","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib113","series-title":"Low affinity blood brain barrier receptor antibodies and uses thereof. United States patent US 10941215B2","author":"Dennis","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib114","series-title":"Compositions and methods comprising histidyl-Trna synthetase splice variants having non-canonical biological activities. United States patent US 10941214B2","author":"Zhou","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib115","series-title":"Immunoglobulin constant region Fc receptor binding agents. United States patent US 10941191B2","author":"Strome","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib116","series-title":"Therapeutic oligonucleotides. United States patent US 10941176B2","author":"O'Neill","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib117","series-title":"Peptides and antibodies for the removal of biofilms. United States patent US 10940204B2","author":"Bakaletz","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib118","series-title":"inventors; Bristol Myers Squibb Co. Serum albumin binding molecules. United States patent US 10934572B2","author":"Gosselin","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib119","series-title":"Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12. United States patent US 10934346B2","author":"Foster","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib120","series-title":"Peptides for angiogenic therapy. United States patent US 10934334B2","author":"astri","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib121","series-title":"Synthesis of the organoarsenical antibiotic arsinothricin and derivatives thereof. United States patent US 10934318B1","author":"Rosen","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib122","series-title":"4-imidazopyridazin-1-yl-benzamides as Btk inhibitors. United States patent US 10934296B2","author":"Barf","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib123","series-title":"Methods of degrading organic pollutants and preventing or treating microbe using Bi2S3-CdS particles. United States patent US 10934176B2","author":"Nawaz","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib124","series-title":"Conjugated lipomers and uses thereof. United States patent US 10933139B2","author":"Dahlman","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib125","series-title":"Inovio pharmaceuticals inc. Vaccines with interleukin-33 as an adjuvant. United states patent US 10933130B2","author":"Weiner","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib126","series-title":"Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte response. United States patent US 10933129B2","author":"Altreuter","year":"2021"},{"key":"10.1016\/j.tube.2022.102208_bib127","series-title":"Synlogic Operating Co Inc. Bacteria engineered to treat a disease or disorder. United States patent US 10933102B2","author":"Falb","year":"2021"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979222000452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979222000452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:46:56Z","timestamp":1761468416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979222000452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":127,"alternative-id":["S1472979222000452"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2022.102208","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanotechnology and tuberculosis: An old disease with new treatment strategies","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2022.102208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102208"}}